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Background: Histamine (HA) regulates the sleep-wake cycle, synaptic plasticity and memory in adult mammals.
Dopaminergic specification in the embryonic ventral midbrain (VM) coincides with increased HA brain levels. To
study the effect of HA receptor stimulation on dopamine neuron generation, we administered HA to dopamine
progenitors, both in vitro and in vivo.
Results: Cultured embryonic day 12 (E12) VM neural stem/progenitor cells expressed transcripts for HA receptors
H1R, H2R and H3R. These undifferentiated progenitors increased intracellular calcium upon HA addition. In HA-treated
cultures, dopamine neurons significantly decreased after activation of H1R. We performed intrauterine injections
in the developing VM to investigate HA effects in vivo. HA administration to E12 rat embryos notably reduced VM
Tyrosine Hydroxylase (TH) staining 2 days later, without affecting GABA neurons in the midbrain, or serotonin
neurons in the mid-hindbrain boundary. qRT-PCR and Western blot analyses confirmed that several markers
important for the generation and maintenance of dopaminergic lineage such as TH, Lmx1a and Lmx1b were
significantly diminished. To identify the cell type susceptible to HA action, we injected embryos of different
developmental stages, and found that neural progenitors (E10 and E12) were responsive, whereas differentiated
dopaminergic neurons (E14 and E16) were not susceptible to HA actions. Proliferation was significantly diminished,
whereas neuronal death was not increased in the VM after HA administration. We injected H1R or H2R antagonists
to identify the receptor responsible for the detrimental effect of HA on dopaminergic lineage and found that
activation of H1R was required.
Conclusion: These results reveal a novel action of HA affecting dopaminergic lineage during VM development.
Keywords: Neural stem cells, Midbrain development, Dopaminergic neurons, Ultrasound injections,
Parkinson’s diseaseBackground
Histamine (HA) is a neurotransmitter that participates
in the sleep cycle, motor activity, synaptic plasticity and
memory [1–5]. The adult mammalian brain contains
somas of HA-producing neurons in the hypothalamic
tuberomamillary nucleus, and its projections reach most
of the CNS [3,4,6]. HA exerts its actions through the ac-
tivation of four G-protein-coupled receptors: H1R-H4R.* Correspondence: ivelasco@ifc.unam.mx
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article, unless otherwise stated.H1R, H2R and H3R are widely distributed throughout
the CNS [6–8], but the presence of H4R in the brain re-
mains unclear [9–11].
During embryonic development, HA is present at
higher concentrations than those observed in the adult
brain [12–14]. HA increases its content at embryonic days
(E) 14–16, and then decreases perinatally [13,15–17]. His-
tidine decarboxylase (HDC), which synthetizes HA, and
the mRNAs for H1R, H2R and H3R [18–21] are also
expressed at these developmental stages [20,22,23]. The
transitory expression of HDC in the midbrain, together
with elevated HA levels, and the expression of HRs,Central Ltd. This is an Open Access article distributed under the terms of the
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suggesting that HA might influence dopamine (DA)
neuron generation in the ventral midbrain (VM). In
rats, differentiated dopaminergic neurons are first iden-
tified at E12 by expression of Tyrosine Hydroxylase
(TH), the rate-limiting enzyme for DA synthesis. The
peak of DA neurogenesis is at E13. By E16, all DA cells
are post-mitotic and their axons are en route to reach
forebrain structures such as the striatum and the cere-
bral cortex [25,26].
On cortical neural stem/progenitor cell (NSPC) cultures,
the effect of activating H1 and H2 receptors has been re-
ported [27]. HA increases cell proliferation by H2R activa-
tion and has a neuronal-differentiating action mediated by
H1R stimulation, probably by rising prospero 1 and neu-
rogenin 1 expression [28] and favoring differentiation to
FOXP2-positive neurons [29]. Furthermore, HA stimu-
lates neuronal differentiation of adult subventricular zone
NSPC [30]. The HA concentrations required to observe
these effects are 100 μM to 1 mM.
Elucidating the developmental pathways that control
neuronal specification in the VM is of great relevance to
increase our knowledge in differentiation of dopamin-
ergic cells. In this work, we aimed to study the effect of
HA on dopaminergic development. We found that HA
is detrimental to dopaminergic differentiation of NSPC
in vitro, and demonstrate that HA administration in vivo
at early developmental stages decreases dopaminergic
induction in the VM through H1R stimulation. This
study establishes the inhibitory relationship of HA to
DA neuron generation during development, and pro-
vides a novel mechanism for the future treatment of
Parkinson’s disease.
Results
Midbrain NSPC cultures are multipotent and express
histaminergic receptors
NSPC have the capacity to self-renew, and the potential
to differentiate into neurons, astrocytes and oligodendro-
cytes. To characterize the expression of NSPC markers, as
well as their capacity to differentiate to neuronal and glial
populations, we cultured VM NSPC isolated from E12 rat
embryos. We maintained these cells in proliferation dur-
ing 4 days in the presence of the mitogen Fibroblast
growth factor (FGF)-2, and then induced differentiation
for 6 days after removal of FGF-2. We found that a very
high proportion of these cells express Sox2, Vimentin and
Nestin, which are markers widely used to identify undif-
ferentiated NSPC (Figure 1A). After removing FGF-2
from cultures, cells readily differentiate into neurons
(MAP2- and β-III Tubulin-positive), astrocytes (Glial
Fibrillary Acidic Protein, GFAP-positive) and oligoden-
drocytes (O4-positive) (Figure 1B), confirming that our
cultures are indeed NSPC.Previous work has demonstrated that mRNAs for his-
taminergic receptors are present in rodent embryos from
E14 onwards [18,20,21], but no information has been
reported regarding the expression of these receptors at
earlier stages of embryogenesis neither in the VM tissue,
nor in midbrain NSPC in vitro. Therefore, using primers
verified to amplify HA receptors [27], we examined
whether these receptors were present in cultured VM
NSPC, before and after differentiation. We found by RT-
PCR that proliferative and differentiated VM NSPC cul-
tures, isolated from E12 rat embryos, express transcripts
of H1R, H2R, and three isoforms reported for the H3R,
which are generated by alternative splicing [19,21,31,32]
(Figure 2A). The VM tissue without culture also had
mRNAs for H1, H2 and H3 receptors (data not shown).
We also performed Western blot analyses and found that
the corresponding proteins for H1R and H2R were present
in cultured NSPC (Figure 2B) and in VM tissue (data not
shown). Even when the level of mRNA for H1 and H2
receptors was low, a single band was clearly detected,
showing that H1R and H2R proteins are present in E12
cultured VM NSPC.
HA increases intracellular calcium in VM NSPC
Calcium (Ca2+) is an important regulator of various
neuronal functions. During the formation of CNS, Ca2+
signaling is involved in the regulation of processes such
as neural induction and differentiation of neural progen-
itors into neurons and glia, in a defined spatiotemporal
pattern [33,34]. Since the activation of H1R leads to the
accumulation of Ca2+ as a second messenger, we tested
if undifferentiated VM NSPC were responsive to HA
stimulation by elevating intracellular Ca2+ concentration
([Ca2+]i). To address this hypothesis, we loaded cultured
Nestin + VM NSPC with the ratiometric calcium probe
Fura-2 AM, and measured the fluorescence changes
resulting from alternating excitation of Fura-2 between
340 nm and 380 nm (R = F340/F380). We found a signifi-
cant 3-fold increase in [Ca2+]i after the addition of 10 μM
HA to VM NSPC, compared to the basal levels observed
in control conditions (Figure 3), indicating that undiffer-
entiated VM NSPC are responsive to HA. These results
are consistent with our previous work on cerebrocortical
NSPC [29], where 100 μM HA also caused calcium in-
creases in VM cells through H1R activation.
HA increases apoptotic cell death of cultured
undifferentiated midbrain NSPC without affecting
cell proliferation
In order to examine the effects of HA on VM NSPC
proliferation and apoptotic cell death, we treated cul-
tures with increasing concentrations of HA (from 1 μM
to 1 mM) in the presence of FGF-2 for 4 days. We used
BrdU incorporation assays to analyze proliferation and
Figure 1 Ventral midbrain NSPC isolated from E12 rat embryos are multipotent. (A) VM NSPC cultured in the presence of the mitogenic
factor FGF-2 express the markers of undifferentiated cells: Sox2, Vimentin and Nestin in proliferation stage. (B) After 6 days without FGF-2
(differentiation stage), VM NSPC differentiate into the three lineages of Central Nervous System: neurons (β-III Tubulin + and MAP2+), astrocytes
(GFAP+) and oligodendrocytes (O4+), confirming the multipotency of these cultures. Nuclei were stained with Hoechst. Scale bars = 100 μm.
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calculated the percentage of BrdU- and TUNEL-positive
cells relative to the total number of cells in control and
HA-treated cultures and found that HA did not affect
BrdU incorporation (Figure 4A and B). In contrast,
1 mM HA significantly increased the proportion of
TUNEL-positive cells and this effect was prevented by
co-incubation with the H1R antagonist chlorphenir-
amine (Figure 4C and D).
HA decreases the number of dopaminergic neurons in
differentiated VM NSPC
To analyze whether HA has an effect on the differenti-
ation of VM NSPC, cultures were treated for 6 days inthe absence of FGF-2. Then, we evaluated by immuno-
cytochemistry the expression of the neuronal marker
β-III Tubulin. We found that 10 μM HA significantly
increased the percentage of β-III Tubulin -positive
cells from 21% to 37%, compared to control (Figure 5A
and B). Additionally, we analyzed whether HA could
have a role on dopaminergic differentiation by detect-
ing the expression of the rate limiting enzyme for
dopamine synthesis, TH, normalized by the number of
neurons positive to β-III Tubulin. Figure panels 5C
and D show that 1 mM HA significantly reduced the
proportion of dopaminergic neurons when compared
to controls. To establish if the decrease on TH-positive
neurons was mediated by H1R activation, we treated
Figure 2 Histaminergic receptors are expressed in rat NSPC ventral midbrain cultures. (A) RT-PCR experiments to detect H1, H2 and H3
receptor mRNAs in proliferating (Prolif) and differentiated (Diff) cultured cells from E12 VM. One μg of total RNA was used for reverse
transcription. The expression of gene transcripts for H1, H2 and H3 receptors were analyzed by electrophoresis on a 2% agarose gel. Rat adult cerebral
cortex (Ctx) was used as positive control and RNA without retrotranscriptase (−RT) as negative control. (B) Western blot experiments performed to
detect H1 and H2 receptors in E12 midbrain proliferating and differentiated cells. Rat adult cerebral cortex (Ctx) was used as positive control. Thirty μg
of protein were resolved on 8% SDS-PAGE, transferred to nitrocellulose membranes, and probed with anti-HA receptors antibodies. Immunoreactive
bands were detected by enhanced chemiluminescence. In RT-PCR and Western blot experiments, GAPDH was used as control.
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ation with 1 mM HA. We observed a significant re-
covery in the number of TH + cells when HA plus
chlorpheniramine were added, compared to HA alone
(Figure 5E and F).Figure 3 HA stimulation increases intracellular Ca2+ in undifferentiate
variations of [Ca2+]i (A) before, (B) during and (C) after stimulation with 10
alternating excitation of Fura-2 between 340 nm and 380 nm (R = F340/F380
exposed to 10 μM HA. **p < 0.01.In vivo experiments
Intrauterine administration of HA does not modify the
morphology of the VM
In order to test if the effects of HA observed in vitro
were also present in the developing brain in vivo, wed VM NSPC. Fluorescence images of responsive VM NSPC showing
μM HA. (D) Average ratio (R) values of fluorescence resulting from
) are shown. (E) A 3-fold increase was found in proliferating VM NSPC
Figure 4 HA does not alter BrdU incorporation but increases apoptotic cell death of proliferating VM NSPC by activating H1R. The effect of
HA on proliferation and apoptotic cell death was evaluated by BrdU incorporation and TUNEL assays, respectively. (A) Micrographs showing
immunostaining to detect BrdU-positive cells. Hoechst was used for visualization of nuclei. (B) Percentage of BrdU-positive cells. No statistically
significant differences were found. (C) Micrographs showing TUNEL-positive cells (white arrows) and Hoechst-stained nuclei. One mM HA caused a
significant increase in apoptotic cells, which was prevented by chlorpheniramine. (D) Percentage of the total cell number of TUNEL-positive
cells. One millimolar HA-treatment increased the proportion of apoptotic cells compared to control condition. *p < 0.05; **p < 0.01; ***p < 0.001.
The H1R antagonist chlorpheniramine significantly reverted this effect.
##p < 0.01 compared to 1 mM HA. Scale bars = 100 μm.
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ide, which was used without neutralization. In these ex-
periments, vehicle, HA or its receptor’s antagonists were
injected directly into the ventricular lumen of E12 rat em-
bryos. This stage was selected because it precedes the peak
of neurogenesis in the midbrain. We initially injected
25 μg of HA and did not observe any change in neuronal
differentiation relative to vehicle-injected embryos. We
then administered 50 μg of HA, and analyzed the brains
at E14. To evaluate if HA injection reached the VM re-
gion, we co-injected HA with a fluorescent tracer (Cell
tracker), and found that the injected volume was enough
to cover consistently the whole midbrain neuroepithelium
(Figure 6A). There were no morphological differences
between vehicle- and HA-injected embryos, assessed by
hematoxylin-eosin staining in both coronal (Figure 6B)
and sagittal (Figure 6C) sections of VM. To assess a
general alteration of the VM, where TH-positive neu-
rons are generated, the thickness of this region was
measured bilaterally. No significant differences on the
average VM thickness were found between vehicle- and
HA-injected embryos (Figure 6D).HA injection decreases dopaminergic induction in VM
Since we found that HA induced a decrease in TH+ neu-
rons after differentiation of cultured NSPC, we inquired
whether this effect is also present in vivo. For this purpose,
E12 rat embryos were injected in the cerebroventricular
lumen either with vehicle or HA. Embryos were allowed
to develop and then euthanized at E14. HA injection pro-
duced no decrease in TH staining without affecting β-III
Tubulin-positive neurons (Figure 7A). These results sug-
gest that HA is not interfering with neuronal differenti-
ation since the normal pattern of β-III Tubulin-positive
neurons was unaffected. In order to more quantitatively
assess neuronal differentiation and the decline in dopa-
minergic neurons, β-III Tubulin and TH mRNA expres-
sion was evaluated by quantitative RT-PCR in vehicle- and
HA-injected embryos. HA caused a significant decline in
TH transcripts without affecting β-III Tubulin expression
(Figure 7B). In addition, we analyzed by Western blot β-
III Tubulin, TH and other markers specific for VM dopa-
minergic phenotype. HA induced a marked reduction in
TH, Lmx1a, Lmx1b and Pitx3 protein levels relative to ve-
hicle (Figure 7C). These experiments strongly support the
Figure 5 HA promotes neuronal differentiation but decreases dopaminergic neurons in cultured VM NSPC. After proliferation, cells were
kept on differentiating conditions for 6 days (N2 medium without FGF-2) and treated daily with different concentrations of HA (from 1 μM to
1 mM HA). VM NSPCs were analyzed after differentiation. (A) Micrographs showing the neuronal marker β-III Tubulin in control and 10 μM
HA-treated cultures. Nuclei were stained with Hoechst. (B) Quantification of β-III Tubulin labeled cells relative to the total number of cells, showing a
significant increase in the proportion of β-III Tubulin + cells caused by treatment with 10 μM HA. (C) Micrographs of double immunocytochemistry to
detect the neuronal marker β-tubulin III and the dopaminergic marker Tyrosine Hydroxylase (TH) in control and 1 mM HA-treated cultures. Nuclei were
stained with Hoechst. Scale bar = 100 μm. (D) Graph showing the percentage of TH-positive neurons in control and after HA treatments, relative to the
total number of β-Tubulin III-positive cells. TH + neurons were significantly decreased after treatment with 1 mM HA. **p < 0.01. (E) Micrographs
showing the dopaminergic marker TH in control cells, and the decrease caused by 1 mM HA. The H1R antagonist chlorpheniramine was tested either
with or without HA. Nuclei were stained with Hoechst. (F) HA-induced decrease of TH-positive numbers was antagonized by chlorpheniramine. Note
that the percentage of TH-positive cells is lower than in Figure 4D because it is normalized by the total number of cells. *p < 0.05 relative to control;
##p < 0.01 compared to 1 mM HA. Scale bars = 100 μm.
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generation without modifying the proportion of neurons
in the VM.
Injection of HA does not alter GABA or serotonin neurons
We also analyzed other neuronal phenotypes present in
the developing brain in embryos injected at E12. GABAer-
gic neurogenesis in the ventral and the dorsal regions of
the midbrain begins simultaneously with dopaminergic
neurogenesis [35]. GABAergic neurons express GAD65
and/or GAD67; GAD enzymes decarboxylate glutamate to
produce GABA. Labeling of GAD65/67 with an antibodythat recognizes both isoforms did not change after HA ad-
ministration, when evaluated by immunohistochemistry
(Figure 8A) and immunoblot (Figure 8B). The GAD stain-
ing pattern is restricted to the dorso-lateral regions of the
midbrain compared to the ventral-most localization of
dopaminergic neurons. The presence of serotoninergic
neurons was identified by immunostaining against sero-
tonin. The distribution of these neurons with or without
HA was found to be in their normal arrangement in the
most posterior part of the midbrain, close to the hind-
brain, the cerebral regions where most serotoninergic
neurons are generated (Figure 8C).
Figure 6 Intrauterine injections reached the VM and do not alter the midbrain morphology. (A) Bright field and fluorescent images of
an E14 brain injected in E12 with cell tracker and HA. (B) Hematoxylin and eosin staining of E14 ventral midbrain (VM) coronal sections of
vehicle-injected or HA-injected embryos. (C) Comparison of E14 VM sagittal sections stained with hematoxylin and eosin from vehicle- and
HA-injected embryos, where no histological differences were found. Scale bars: 500 μm and 150 μm. (D) To more quantitatively assess the VM,
measurements of the thickness corresponding to the ventral part of the midbrain, where dopaminergic neurons are present, were performed;
the brackets mark the regions used to measure thickness in both sides of the brain. The graph represents the average of thickness in both sides.
No difference between vehicle- and HA-injected embryos was found. Scale bar: 150 μm.
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administered at early stages
In order to establish whether embryos of different devel-
opmental stages were equally susceptible to HA actions as
we observed at E14, we performed injections at E10, E12,
E14 or E16 and analyzed TH expression in VM two days
later in every case. We found that when HA was injected
at E10 and E12, a marked decrease in TH staining was ob-
served. In contrast, when HA was administered at E14 or
E16, the TH expression pattern was indistinguishable from
vehicle-injected embryos (Figure 9), strongly suggesting
that HA is acting on neural precursors, and not on differ-
entiated neurons.
HA decreases cell proliferation without altering cell death
After we found that HA induced a decrease in TH +
neurons in vivo at early developmental stages, we askedwhether this effect was produced by means of decreased
proliferation or increased cell death. We injected embryos
at E12 and coronal sections of vehicle- and HA-injected
E14 embryos were stained with anti-phosphorylated his-
tone H3 (pHH3), a marker for cells in M-phase. The
pHH3 staining pattern of vehicle-injected embryos is
consistent with previous reports [36]. However, the in-
jection of HA caused significantly less pHH3-positive
cells in the VM compared with vehicle-injected embryos
(Figure 10A). We assessed apoptotic cell death in vivo
and found no significant differences caused by HA ad-
ministration (data not shown). We then decided to use
Fluoro Jade staining to detect neuronal death, and found
that HA injection did not modify the proportion of de-
generating cells (Figure 10B). Thus, our results show
that HA is affecting proliferation in vivo without modi-
fying cell death in the VM.
Figure 7 HA injection decreases dopaminergic neurons without affecting β-III Tubulin. (A) Coronal sections of the ventral midbrain from
E14 vehicle- and HA-injected rat embryos stained to detect neurons (β-III Tubulin+) and dopaminergic phenotype (TH+); a representative section
of a vehicle-injected embryo showing many TH-positive neurons while in a similar midbrain section from a representative HA-injected embryo
less TH-positive cells are present. Nuclei were detected with Hoechst. Inner white squares in the merge images represent the higher magnifications
shown at the bottom. Scale bars: 150 μm and 50 μm for the low-power and high-power pictures, respectively. (B) β-III Tubulin and TH expression
by qRT-PCR from E14 vehicle- and HA-injected embryos, with β-III Tubulin presenting no change, and a significant decrease in TH caused by
HA. **p < 0.01. (C) Densitometric analyses of the effect of HA administration on protein levels of β-III Tubulin and diverse factors involved in
dopaminergic specification and phenotype. HA injection decreased the protein level of TH, Lmx1a, Lmx1b and Pitx3 in midbrain tissue from
E14 HA-injected embryos without affecting the generation of neurons, compared to the vehicle-injected condition. Values were normalized to
GAPDH signal. *p < 0.05.
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by H1R
In order to identify which receptor was responsible for
the observed HA effects, injections of H1R or H2R antago-
nists, alone or in combination with HA, were performed.We analyzed the TH staining pattern in VM coronal sec-
tions of E14 embryos injected 2 days before. The H1R an-
tagonist chlorpheniramine, injected at high doses (25 μg
or 50 μg), markedly affected the normal development of
the embryos, causing non-specific effects. When we
Figure 8 HA does not alter GABAergic or serotoninergic neurons. (A) Coronal sections of the ventral midbrain from E14 vehicle- and
HA-injected rat embryos stained to identify neurons (β-III Tubulin+) and GABA-synthesizing cells (anti-GAD65/67+ antibody); vehicle-injected
embryos had the same proportion of GAD65/67+ cells when compared to HA-injected embryos. Nuclei were stained with Hoechst. Scale bar:
150 μm. (B) HA did not modify the level of GAD65/67 protein in E14 midbrain tissue compared to vehicle-injected embryos by Western blot.
The graph represents the densitometric analysis of GAD65/67 protein content where no significant effects were found; values were normalized
to GAPDH. (C) Coronal sections of the ventral midbrain from vehicle- and HA-injected E14 embryos stained with β-III Tubulin and serotonin
antibodies, where no differences in serotoninergic neurons are observed. Scale bar: 150 μm.
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mal morphology of the treated embryos (Figure 11A).
This latter dose of chlorpheniramine did not affect the ex-
pression of TH (Figure 11B); however, when co-injected
with HA (Figure 12C), chlorpheniramine blocked HA-
induced decrease in TH (Figure 12B), resulting in a TH
staining similar to vehicle-injected embryos (Figure 12A).
Cimetidine, a specific H2R antagonist, at the tested dose
(50 μg), did not modify the normal embryo development
nor TH staining, when injected without HA (Figure 11B).
Co-injection of cimetidine with HA did not antagonize
the effect triggered by HA (Figure 12D). These results
demonstrate that the decrease of TH+ cells is mediated
through the activation of H1R.
Discussion
In this study we report that: i) midbrain NSPC express
HA receptors; ii) HA stimulus increases intracellular
calcium in proliferative VM NSPC; iii) one millimolar
HA promotes apoptotic death of cultured VM NSPC by
activating H1R; iv) Ten μM HA increases neuronaldifferentiation, but 1 mM HA decreases the number of
differentiated dopaminergic neurons, in a H1R-dependent
fashion, on VM NSPC cultures; v) HA injection at E12 de-
creases dopaminergic induction in VM without altering
GABA or serotonin neurons in vivo; vi) HA interferes
with dopaminergic development only when adminis-
tered at early developmental stages; vii) HA impaired
cell proliferation in the VM in vivo and viii) the effect of
HA on dopaminergic differentiation is mediated by acti-
vation of H1R.
We found that H1 and H2 receptors are present at
both mRNA and protein levels in proliferating and dif-
ferentiated cultured VM NSPC. We showed that upon
HA stimulation, undifferentiated cultures of VM NSPC
significantly increased the cytoplasmic Ca2+ concentra-
tion. This data strongly suggest the presence of functional
H1R coupled to the canonical calcium response in VM
NSPC, consistent with the calcium responses evoked by
100 μM HA in cortical NSPC, which is blocked by
chlorpheniramine [29], supporting the notion that H1R
activation in undifferentiated NSPC occurs in both the
Figure 9 HA acts on early dopamine neural precursors but differentiated dopamine neurons are resistant. Sagittal sections of the VM
from vehicle- and HA-treated rat embryos that were injected at different developmental stages, and analyzed two days later. Sections were
stained to detect neurons (β-III Tubulin+) and dopaminergic phenotype (TH+); nuclei were detected with Hoechst. The decreasing effect of
HA injection on dopaminergic phenotype is evident only when injected at early developmental stages (E10-E12 or E12-E14) but not at later
developmental stages (E14-E16 or E16-E18). For the vehicle-injected E10-E12 embryos, only a few TH + neurons were found in the isthmic region
and these neurons were absent in HA-injected organisms. Scale bars are indicated in the figure.
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cellular Ca2+ regulates neurogenesis as well as neurite/
nerve growth and axonal pathfinding [34,37,38]. In cor-
tical NSPC, H1R was responsible for the increased neur-
onal differentiation caused by HA. We explored the
effect of HA on proliferation, cell death and differenti-
ation of cultured midbrain NSPC. No significant differ-
ences on cell proliferation were found in HA-treated
VM NSPC, when compared to control conditions. Re-
garding cell death, we observed an increasing effect of
HA on apoptosis with 1 mM HA, which was clearly pre-
vented by chlorpheniramine. We have previously reported
that HA, through H1R activation, increases differentiation
of E14 cortical NSPC to neurons that are positive for
FOXP2, a marker of deep cortical layers [27,29]. In con-
trast, in this study we found that in E12 VM NSPC,
10 μM HA increased neurogenesis and 1 mM HA affected
DA neuron generation. These results highlight that the ef-
fects of HA vary depending on the studied brain region
and the concentration of HA used. In VM NSPC, the de-
crease in TH+ cells was mediated by H1R.
Previous studies have shown the expression patterns
of HA-immunoreactive neurons and HRs at different
stages of development [15]. HA-immunoreactive neu-
rons are first detected on E13 in the regions of mesen-
cephalon and metencephalon, this expression pattern
remains until E17 and gradually decreases towards birth
[15]. The expression patterns of HRs were reported at
later stages of development (from E14 onwards) by in
situ hybridization [18,20]. We now show by RT-PCR andWestern blot the presence of H1 and H2 receptors in
E12 cultured VM NSPC.
Ultrasound guided-injection is a valuable technique
that allows visualization and manipulation of embryos
at specific developmental stages [39–41]. We did not
find morphological differences between the vehicle- and
HA-injected embryos, assessed by hematoxylin-eosin
staining and the VM thickness, which allowed us to con-
fidently proceed to analyze the effect of HA on midbrain
development. We corroborated, by co-injections with
Cell tracker, that HA reached all cells in the VM. When
we evaluated neuronal differentiation by immunostain-
ing, qRT-PCR and immunoblot, HA did not modify
β-III Tubulin expression, suggesting that HA is not pre-
cluding neuronal differentiation. However, consistent
with the data in VM NSPC cultures, when the limiting
enzyme for DA synthesis, TH, was evaluated by immuno-
histochemistry, qRT-PCR and Western blot, we found sig-
nificant decreases after HA application at E12, pointing
out to a detrimental effect on dopaminergic neurons
in vivo. These results suggest that HA might be affecting
either DA specification and/or differentiation. To study if
DA specification was being affected, we analyzed the
expression of the Lim homeodomain genes Lmx1a and
Lmx1b, which are specific markers for midbrain dopamin-
ergic precursors. Lmx1a is an early marker of dividing
mesencephalic precursors in the floor plate ventricular
cells at early stages of development, instructing their dif-
ferentiation into the midbrain dopaminergic phenotype,
while Lmx1b is essential for the generation of properly
Figure 10 HA diminishes proliferation without altering cell death in VM. (A) Proliferation was assessed by staining with the mitotic marker
pHH3 in coronal sections of the ventral midbrain from E14 vehicle- and HA-injected embryos. HA-injected embryos had significantly less pHH3+
cells when compared to vehicle-injected embryos. Nuclei were stained with Hoechst. *p < 0.05. (B) Coronal VM sections showing Fluoro Jade
staining where no significant differences were observed in degenerating cells. Scale bar: 150 μm.
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gional specification [42,43]. HA significantly decreased the
expression levels of both markers. Pitx3, a protein im-
portant for maintenance of dopaminergic identity, also
decreased in HA-injected embryos, relative to vehicle-
treated animals. To further support that HA is acting on
DA precursors, E10 and E12 embryos were injected
either with vehicle or HA. We demonstrated that the
impairing effect of HA over the dopaminergic lineage is
present in both developmental stages. In sharp contrast,
DA neurons were unaffected when HA was applied at
E14 or E16, when most cells already differentiated to
dopaminergic neurons. These results strongly support
that detrimental action of HA is on VM dopaminergic
neural precursors rather than early differentiated neurons.
We found that HA did not modify BrdU incorporation
in cultured VM NSPC, but significantly decreased the
number of ventricular pHH3-positive cells in vivo. This
different effect of HA on proliferation might be ex-
plained by the fact that BrdU was added to cultures for3 h, and is incorporated by cells in the S phase of cell
cycle, whereas pHH3 is present in cells undergoing mi-
toses. An additional factor to consider is that 100 μM
HA caused a significant increase of BrdU incorporation
in cultured cortical NSPC in the presence of daily-added
10 ng/ml FGF-2 [27], the same conditions used here for
VM NSPC. A potentiation of thymidine incorporation has
also been reported for tracheal smooth muscle human
cells incubated with 10 ng/ml Epidermal Growth Factor
and 10 μM HA, compared to the growth factor-only con-
dition; this increased proliferation was associated to acti-
vation of Akt with participation of Gq/11 receptors [44]. It
is possible that in cultured VM cells there are subpopu-
lations that differentially respond to HA: some might
decrease (i.e. dopaminergic precursors), while others (non-
dopaminergic cells) could increase BrdU incorporation,
resulting in no overall changes after HA addition. This
possibility is supported by the fact that HA caused a sig-
nificant decrease in the number of differentiated dopamin-
ergic neurons both in vitro and in vivo.
Figure 11 High doses of chlorpheniramine affect normal embryonic development but neither chlorpheniramine nor cimetidine affects
dopaminergic neurons. (A) Micrographs from E14 rat embryos injected at E12 with different doses of the H1R antagonist, chlorpheniramine.
Fifty and twenty-five micrograms interfered with normal development, while 15 μg allows normal development of the embryo. (B) TH and β-III
Tubulin staining in coronal sections of the VM from E14 rat embryos injected with 15 μg of the H1R antagonist, chlorpheniramine or 50 μg of the
H2R antagonist, cimetidine. The staining patterns were not modified by these antagonists. Scale bar: 150 μm.
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phenotypes present in midbrain-surrounding regions. Both
serotoninergic and dopaminergic neurons arise from the
ventral-most neuroepithelial progenitors, although at
different rostro-caudal levels [45]. GABAergic cells are
present in the substantia nigra pars reticulata and to
some extent within the substantia nigra pars compacta
and also in the ventral tegmental area [35]. Here, we dem-
onstrate that the HA effect on midbrain development was
selective for dopaminergic phenotype without affecting
the generation of GABA neurons. In line with these
findings, serotonin neurons, which are formed in thehindbrain very close to the midbrain-hindbrain bound-
ary, were unaffected by HA.
In order to identify the cellular mechanism by which
HA was exerting its action on decreasing TH + dopamin-
ergic neurons, we co-injected HA with H1R or H2R antag-
onists. We found that only chlorpheniramine, a selective
H1R antagonist, completely prevented the impairing ac-
tion of HA over DA neurons. Our data support the hy-
pothesis that HA action is on precursor dopaminergic
cells by activation of H1R. We suggest that HA might be
acting as a detrimental signal during early stages of DA
specification. As we showed in vitro, incubation with HA
Figure 12 The H1R antagonist chlorpheniramine, but not the H2R antagonist cimetidine, abolished the deleterious effect of HA
administration on dopaminergic differentiation. (A-D) TH and β-III Tubulin staining in coronal sections of the VM from E14 rat embryos with
the indicated treatments. (A) Normal pattern of dopaminergic neuron staining in a vehicle-injected embryo. (B) Decrease in TH immunoreactivity
due to HA administration. (C) Protective effect of the H1R antagonist chlorpheniramine on HA-induced decrease of TH immunoreactivity.
(D) Administration of HA and the H2R antagonist cimetidine did not modify dopaminergic neurons compared to HA-injected embryos. Scale
bar: 150 μm.
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NSPC, which might suggest that the mechanistic basis
of HA effect over NSPC population affecting dopamin-
ergic differentiation/specification involves intracellular
Ca2+. Interestingly, Ca2+ signaling appears to control
NSPC proliferation, regulating the switch from prolifer-
ation to neuronal differentiation [46]. For instance, in
human NSPC, mobilization of IP3-dependent Ca
2+ stores
lengthens the cell cycle and increases the number of inter-
mediate neural progenitors [34]. In this model, Ca2+ con-
trols the duration of cell cycle by increasing the level of
p53 protein, a known regulator of the cyclin-dependent
kinase inhibitor p21 [47]. We have previously shown in
cortical NSPC cultures the effect of HA on cell division
patterns, evaluating asymmetric and symmetric divisions
[28]. In the developing VM, proliferating cells are present
in close to the ventricular zone [36]; we show that the
number of mitotic cells is decreased by HA injection
in vivo, and this could be a contributing mechanism for
the decreased number of dopaminergic neurons.
The effects of artificially administering HA during VM
development are clear, but we did not directly assess
the participation of endogenous HA on dopaminergicdevelopment for example by decreasing its levels by inhi-
biting Histidine decarboxylase activity; nonetheless, the
injection of H1 or H2 receptor antagonists alone did not
modify TH staining, suggesting that the endogenous HA
levels are not sufficient to affect dopaminergic develop-
ment. Interestingly, the participation of HA in the patho-
genesis of Parkinson’s disease in adult organisms has been
suggested by previous work. For example, there is an in-
crease in brain HA content in post-mortem putamen and
substantia nigra [48] and HA blood levels are increased in
parkinsonian patients [49]. Also, the number of histamin-
ergic fibers innervating the substantia nigra is increased in
individuals suffering Parkinson’s disease relative to controls
[48,50]. In addition to these suggestive data, there is experi-
mental evidence showing that HA can affect differentiated
dopaminergic neurons in the adult brain. Direct infusion of
HA in the rodent substantia nigra leads to a selective dam-
age of DA neurons [51]. One of the most widely used ani-
mal model for Parkinson’s disease is the intracerebral
injection of the DA neurotoxin 6-hydroxydopamine in one
hemisphere. When endogenous brain HA levels were in-
creased or decreased, 6-hydroxydopamine-induced damage
was potentiated or inhibited, respectively, assessed by TH
Table 1 Primer sequences for detection of histaminergic
receptors by end-point RT-PCR
Gene Sense primer Antisense primer
H1R F: 5′-CTTCTACCTCCCCACTTTg
CT-3′
R: 5′-TTCCCTTTCCCCCTCTTg-3′
H2R F: 5′-TTCTTggACTCCTggTgCTg
C-3′
R: 5′-CATgCCCCCTCTggTCCC-3′
H3R F: 5′-CCAgAACCCCCACCAgA
Tg-3′
R: 5′-CCAgCAgAgCCCAAAgA
Tg-3′
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ine administration. Supporting the participation of HA in
the damage induced by this neurotoxin, the H1R antagonist
pyrilamine, significantly, albeit transiently, decreased DA
neuron degeneration; the H2R antagonist cimetidine, did
not modify the 6-hydroxydopamine-induced damage [52].
Alternative mechanisms for the deleterious effects of
HA on DA cells can include activation of microglial cells.
In the adult substantia nigra injection of HA generates a
microglial reaction, promoting dopaminergic cell death
[51]. The possibility that microglia might contribute to
DA degeneration in our model needs to be tested. There
is evidence that microglia are present at this developmen-
tal stages [53], and that activated microglial cells reduce
the number of neural precursor cells by phagocytosis in
the developing cerebral cortex [54].
Conclusion
Our findings reveal an unexpected role of HA receptor
activation during embryogenesis in a specific neuronal
phenotype. These effects are relevant for its significance
as a possible therapeutic target in CNS pathologies that
involve the interaction between both histamine and dopa-
mine systems. In conclusion, our study contributes to the
knowledge of factors participating on the generation and
degeneration of DA neurons and reveals novel actions of
HA during midbrain development, which might lead to
design new and more specific protocols for the gener-
ation of dopaminergic neurons and future therapies for
Parkinson’s disease.
Methods
Cell culture
Multipotent NSPC were isolated from E12-E12.5 em-
bryos obtained from time-pregnant Wistar rats as de-
scribed [27]. For simplicity, we only use E12 to designate
these embryos and the same criterion applies for other
embryonic stages. VM was dissected in Krebs solution
then mechanically dissociated. Cells were recovered by
centrifugation. Isolated cells were cultured on plastic
ware treated with 15 μg/ml poly-L-ornithine (Sigma) and
1 μg/mL human Fibronectin (Invitrogen) in N2 medium
(DMEM/F12 1:1, supplemented with 25 μg/L of human in-
sulin, 30 nM sodium selenite, 100 μM putrescine, 20 nM
progesterone and 100 mg/L of apotransferrin) containing
10 ng/mL of basic fibroblast growth factor (FGF-2; Pepro-
tech). Cultures were maintained at 37°C in humidified 5%
CO2/95% air atmosphere. These cultures were considered
as passage (P) 0. When cultures reached 80% confluence,
cells were detached with 0.1 mM EDTA in phosphate
buffered saline (PBS) and re-plated to P1. Cells were
maintained under proliferation conditions for 4 days in
control (N2 medium + 10 ng/ml FGF-2) and experimen-
tal conditions that vary concentrations of HA (from1 μM to 1 mM) with or without HA receptor antago-
nists. Differentiation was promoted by removal of FGF-
2 during 6 additional days in control and experimental
conditions. HA antagonists for H1R (1 μM chlorphenir-
amine, Sigma), H2R (30 μM cimetidine, Sigma) were
added daily to HA-treated cells during proliferation and
differentiation stages. For immunocytochemistry analysis,
BrdU and TUNEL assays, cells were seeded at 1.5×104/
well in 24-well plates (Corning). For RNA extraction, cells
were seeded at 3×105/well in 6-well plates (Corning). HA
dihydrochloride was used without neutralization.
RNA extraction, RT-PCR and Real-Time RT-PCR
Total RNA was isolated from proliferating cultures, dif-
ferentiated cultures, and midbrain tissue from ultra-
sound injected and control embryos using TRIZOL
reagent (Invitrogen). One μg of RNA was reverse tran-
scribed using dNTPs, 100 U of Superscript III Reverse
Transcriptase, 50 μM of random hexamers and 40 U of
Recombinant RNase Inhibitor (Invitrogen). PCR reac-
tions were performed using 100 ng of cDNA, 2 U of re-
combinant Taq DNA polymerase (Invitrogen), 20 pmol
of each oligonucleotide, 500 μM dNTPs (Sigma) and
1.5 mM MgCl2. PCR products were analyzed by electro-
phoresis to determine their molecular weights after eth-
idium bromide staining. The sequences of the PCR
products were verified and correspond to the indicated
HA receptor. Reactions with RNA in the absence of ret-
rotranscription were included as negative controls. RNA
extracted from adult rat cerebral cortex was used as a
positive control for HA receptors. The forward (F) and
reverse (R) primers listed in Table 1 were used.
These primers have been used previously by our group
[27] and after retrotranscription and amplification, PCR
products were extracted from the gel and sequenced,
confirming that these sequences correspond to H1, H2
and the 3 isoforms of H3 receptors.
For qRT-PCR [55], we used 100 ng of the synthesized
cDNA, 2.5 U of recombinant Taq DNA polymerase (Invi-
trogen), 0.4 mM of each oligonucleotide and dNTPs,
1.5 mM MgCl2 and 5 μM Syto 9 (Invitrogen). Quantitative
analysis of cDNA amplification was performed using the
Rotor Gene 6000 System (Corbett Life Science). Melting
curves were performed in every reaction to ensure that
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used as loading control for all reactions and every tran-
script value was normalized to GAPDH expression. The
2exp (−ΔΔCt) method was used to determine the relative
expression of each gene compared to control condition.
The primers listed in Table 2 were used.
Western blot
Cells were cultured and seeded at 3.5×104/well in 6-well
plates (Corning) in control and experimental conditions,
following standard protocols [27,56]. Briefly, cells were
homogenized in lysis buffer (25 mM Tris–HCl pH 7, 1%
IGEPAL, 100 mM NaCl) supplemented with protease in-
hibitors (Complete mini, Roche). Proteins were obtained
by centrifugation at 13 800 g at 4°C for 15 min, and quan-
tified by Bradford assay (BioRad). Proteins (30 μg) were
resolved on 8% sodium dodecyl sulfate–polyacrylamide
gel electrophoresis and transferred to nitrocellulose mem-
branes (Amersham Bioscience). The membranes were
blocked with 5% non-fat milk and incubated overnight
with primary antibodies. Pre-stained markers (Invitrogen)
were included for size determination. The following
antibodies were used: rabbit anti-rat H1R polyclonal
antibody (1:1500, Santa Cruz Biotechnology); goat anti-
rat H2R polyclonal antibody (1:1500, Santa Cruz Bio-
technology); rabbit anti-Lmx1a polyclonal antibody
(1:100, Abcam); rabbit anti-Lmx1b polyclonal antibody
(1:100, Abcam); rabbit polyclonal anti-tyrosine hydroxylase
(TH, 1:1000; Pel-freez) and rabbit anti-Pitx3 polyclonal
antibody (1:500, Zymed). Membranes were washed and
incubated with corresponding horseradish peroxidase-
coupled secondary antibodies (1:10 000, Santa Cruz Bio-
technology) for 2 hours. Immunoreactive bands were
detected using enhanced chemiluminescence method
(Amersham Bioscience) and developed on photographic
film (Kodak).
Immunocytochemistry
Cells were fixed with 4% paraformaldehyde in PBS, pH 7.4
at the end of proliferation and differentiation stages.
Immunocytochemistry assays were performed following
standard protocols [57]. Briefly, cells were permeabilized
and blocked for 1 hour with 0.3% Triton X-100 and 10%
normal goat serum (NGS) in PBS. Cells were incubatedTable 2 Primer sequences for detection of transcripts by
qRT-PCR
Gene Sense primer Antisense primer
β-III Tubulin F: 5′-ggCCTTTggACACC
TATTCA-3′
R: 5′-TgCAggCAgTCACAAT
TCTC-3′
TH F: 5′-CCACTggAggCTgTgg
TATT-3′
R: 5′-CCgggTCTCTAAgTggT
gAA-3′
GAPDH F: 5′-gTggACCTCATggCCTA
CAT-3′
R: 5′-ggATggAATTgTgAggg
AgA-3′overnight at 4°C with the following primary antibodies
diluted in PBS containing 10% NGS: rabbit polyclonal
anti-β-III Tubulin (1:2000, Covance); rabbit polyclonal
anti-glial fibrillary acidic protein (GFAP; 1:2000, DAKO);
mouse monoclonal antibody anti-microtubule associated
protein 2 (MAP2; 1:500, Chemicon); mouse monoclonal
anti-Nestin (1:100, Developmental Studies Hybridoma
Bank); rabbit anti-Nestin (1:1000, Covance); rabbit poly-
clonal anti-TH (1:1000; Pel-freez); rabbit polyclonal
anti-Sox2 (1:200; Millipore). Appropriate Alexa-Fluor
secondary antibodies were used diluted in PBS (1:1000;
Molecular Probes) containing 10% NGS. Nuclei were
stained with Hoechst 33258 (1 ng/mL; Sigma). Immunos-
tainings were analyzed with an epifluorescence micro-
scope (Nikon, Eclipse TE2000-U) and photographed with
a Nikon digital camera (DMX1200 F). Negative controls
were performed in the absence of primary antibodies and
showed no unspecific staining.
BrdU incorporation assay
Cells treated with FGF-2 were incubated for 3 hours
with 10 μM 5-bromo-2-deoxyuridine (BrdU, Roche),
washed with medium and fixed with 4% paraformaldehyde
in PBS 21 h later [27]. After fixation, cells were incubated
with 1 N HCl for 30 min at 25°C, and neutralized by
washing with 0.1 M borate buffer, pH 8.5. Preparations
were blocked for 1 h with 10% NGS (Invitrogen) and 0.3%
Triton X-100 (Sigma) in PBS. Cells were incubated over-
night at 4°C with monoclonal rat anti-BrdU antibody
(1:100; Accurate) followed by three washes with 1%
bovine serum albumin in PBS. Alexa-Fluor 488 goat
anti-rat IgG was added (1:1000, Invitrogen) in blocking
solution for 1 h at RT and washed three times with
PBS. Nuclei were stained with Hoechst 33258 (1 ng/mL;
Sigma).
TUNEL assay
Proliferating and differentiated cells were fixed with
4% paraformaldehyde in PBS, and subsequently washed
three times with PBS, pH = 7.4 [27]. For detection of
apoptotic cells, the Terminal deoxytransferase-mediated
deoxyuridine triphosphate nick-end labeling kit (TUNEL,
InSitu Cell Death Detection Kit, Roche Diagnostics) was
used to evaluate the effect of HA on cell death. Apoptotic
cells were visualized by fluorescence microscopy.
Fluoro Jade staining
Fluoro Jade was used to label and quantify degenerating
neurons in the VM. The sections were mounted on slides
and air-dried. The slides were dipped in absolute ethanol
for 3 min followed by 1 min in 70% ethanol and washed
in deionized water for 1 min. Tissue was then oxidized
with a 0.06% KMnO4 solution diluted in PBS for 15 min,
followed by three rinses with deionized water. From this
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sections were stained with a 0.001% solution of Fluoro-
Jade in 0.1% acetic acid for 30 min. Slides were rinsed with
water and air-dried. The slides were cleared in xylene and
coverslipped with DPX mounting medium [58,59].
Cell counting
Cell counts from BrdU, immunocytochemistry, TUNEL,
phosphorylated histone H3 (pHH3) and Fluoro Jade exper-
iments were performed from digital pictures. Quantifica-
tion of cells was performed by using the ImageJ software
considering the total number of Hoechst-stained nuclei
(total cells), in at least 10 random fields from a minimum
of 3 independent experiments.
Intracellular Ca2+ imaging
Proliferating VM NSPC in suspension were loaded with
the Ca2+-sensitive fluorescence indicator Fura-2 AM
(Invitrogen) at a final concentration of 5 μM at 37°C for
45 min [29]. Loaded cells were centrifuged and seeded at
1×105 cells on 3.5 cm glass bottom dishes (MatTek Corp)
treated with 15 mg/mL poly-L-ornithine (Sigma) and
1 μg/ml human Fibronectin (Invitrogen) in N2 medium.
After 2 hours, attached cells were incubated in Hank’s so-
lution (137 mM NaCl, 5 mM KCl, 0.3 mM NaH2PO4,
0.8 mM MgSO4, 1 mM MgCl2, 5 mM glucose, 2 mM glu-
tamine, 10 mM Tris–HCl without CaCl2; pH 7.4) at 37°C
for 10 minutes. Subsequently, Hank’s solution was re-
moved and new solution with 5 mM CaCl2 was added.
UV excitation was set to alternate between 340 and
380 nm and the emission was monitored at 510 nm in a
Carl Zeiss microscope. Images and the emission ratio gen-
erated between both excitations wavelengths (R = E340/
E380) were obtained and analyzed using AxioVision
software.
Ultrasound guided injections
We used timed-pregnant Wistar rats with embryos at
gestational ages E10, E12, E14 and E16 to perform
ultrasound-guided injections. All animal procedures were
approved by the Instituto de Fisiología Celular Animal
Use and Care Committee and conformed to Mexican and
NIH guidelines. All injections were performed by dupli-
cate or triplicate in different embryos from the same dam,
and repeated at least in 3 different pregnant rats. Control
and experimental animals were included in the same preg-
nant rat, but to make sure that the different conditions do
not mix, each group was evaluated in a single uterine
horn. The results were reproducible when we analyzed
embryos from different dams. To perform ultrasound
guided injections [40], we used an MHF-1 Ultraview
UltraSound System (E-Technologies) with a focal distance
of 7 mm for imaging. Rats were deeply anesthetized in
a chamber and then maintained with a facemask toadminister inhaled sevoflurane (5% for induction and
1% for maintenance). We performed midline laparotomy,
uterine horns were carefully exposed and the number of
embryos was recorded. Intraventricular injections were
performed through the uterine wall using pulled microca-
pillaries (borosilicate glass, Sutter Instruments). The glass
needles were visualized in the ultrasound imaging system
and the verification of the site of injection in the lateral
ventricles was made during the procedure by observing the
liquid going out of the needle. HA, chlorpheniramine (H1R
antagonist) or cimetidine (H2R antagonist) were injected
on the ventricular lumen at different doses in a final vol-
ume of 2 μl aided by an automatic injector (Quintessential
injector, Stoelting). The injected amount was of HA
dihydrochloride, which was used without neutralization.
DMSO and Cell Tracker (Invitrogen) injections were
performed as controls. Once the desired number of em-
bryos was injected, the uterus was repositioned in its
physiological site. The incisions of the abdominal muscle
and skin were stitched with separate sutures. Finally we
applied Buprenorphine as analgesic (0.1 mg/kg, Pisa La-
boratories) and animals were monitored and left to re-
cover. Two days after the injections, pregnant rats were
euthanized by overdose of the anesthetic Sodium pento-
barbital (Pfizer), and identified embryos were recovered
for analysis. We performed the following number of
successfully injected E12 embryos: vehicle: 48; HA: 12;
chlorpheniramine: 9; cimetidine: 9; HA plus chlorphen-
iramine: 9; HA plus cimetidine: 9. The number of dams
used was 18.
Immunohistochemistry
Embryos were removed and transferred to PBS. Subse-
quently, the embryos were fixed by immersion overnight
in 4% PFA in PBS at 4°C. Thereafter, the tissues were
cryoprotected overnight in 30% (v/v) sucrose, embedded
in Tissue Freezing Medium (Tissue-Tek, Zakura Finetek)
and frozen. Sagittal and coronal sections (20 μm) were
obtained on a cryostat (Leica). For immunohistochemistry,
slides were rehydrated in PBS. Tissue sections were
permeabilized and blocked for 1 hour at RT with 0.3%
Triton X-100 and 10% NGS in PBS. Slides were incubated
overnight at 4°C with the following primary antibodies di-
luted in PBS containing 10% NGS: rabbit polyclonal anti-
pHH3 (1:250, Cell Signaling), rabbit polyclonal anti-β-III
Tubulin (1:1000, Babco Covance); mouse monoclonal anti-
Nestin (1:100, Developmental Studies Hybridoma Bank);
rabbit polyclonal anti-tyrosine hydroxylase (TH; 1:1000,
Pel-freez); rabbit polyclonal anti-GAD65/67 (1:500, Milli-
pore); rabbit polyclonal anti-serotonin (1:500, Sigma). Sub-
sequently, the sections were washed three times for
5 minutes in PBS and incubated with the secondary anti-
bodies Alexa-Fluor 488 anti-rabbit IgG and Alexa-Fluor
568 anti-mouse IgG (1:500; Molecular Probes) in PBS
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Hoechst 33258 (1 ng/mL). After three further washes in
PBS, the sections were mounted in Aqua Poly/Mount
(Polysciences, Inc.) Immunostainings were analyzed with
an epifluorescence microscope (Nikon, Eclipse TE2000-U)
and photographed with a Nikon digital camera (DMX1200
F). Some images were acquired with a FV1000 Olympus
confocal microscope. Negative controls were performed
in the absence of primary antibodies and showed no un-
specific staining.
Statistical analysis
We performed 3–5 independent experiments, defined as
duplicate or triplicate experiments from a different preg-
nant rat. All data are presented as mean ± standard error
of mean (S.E.M). One-way ANOVA was performed for
statistical analysis and multiple comparisons between
treated and control groups were made using the post-
hoc Student-Newman-Keuls test. Differences were con-
sidered statistically significant at P ≤ 0.05. Graphs were
generated using GraphPad Prism software.
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